Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus

References

• Ogihara T, Kikuchi K, Matsuoka H, et al. Japanese society of Hypertension Committee. The Japanese Society Of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009;32:3–107.
   Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462–536.
   Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121–58.
   Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–17.
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–21.
   Google Scholar
• Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266–81.
   PubMed Web of Science ®Google Scholar
• Jansen PM, Frenkel WJ, van den Born BJ, et al. Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension. J Hypertension 2013;31:404–13.
   PubMed Web of Science ®Google Scholar
• Wada T, Kenmochi H, Miyashita Y, et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 2010;151:2040–9.
   PubMed Web of Science ®Google Scholar
• Hirata A, Maeda N, Hiuge A, et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009;84:164–72.
   PubMed Web of Science ®Google Scholar
• Karashima S, Takeda Y, Yoneda T, et al. Comparison of eplerenone and spironolactone for the treatment with primary aldosteronism. Hypertens Res 2015 (in press)
   Google Scholar
• Katz A, Nambi SS, Mather K, Baron AD, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85:2402–10.
   PubMed Web of Science ®Google Scholar
• Takeda Y, Furukawa K, Inaba S, et al. Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldosteronism. J Clin Endocrinol Metab 1999;84:1633–1637.
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343–2349
   PubMed Web of Science ®Google Scholar
• Sato A. Mineralocorticoid receptor antagonists: their use and differentiation in Japan. Hypertens Res 2013;36:185–90.
   PubMed Web of Science ®Google Scholar
• Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999;48:756–60.
   PubMed Web of Science ®Google Scholar
• Prisant LM, Krum H, Roniker B, et al. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J Clin Pharmacol 2003;43:1203–10.
   PubMed Web of Science ®Google Scholar
• Rega-Kaun G, Kaun C, Wojta J. More than a simple storage organ: adipose tissue as a source of adipokines involved in cardiovascular disease. Thromb Haemost 2013;110:641–50.
   PubMed Web of Science ®Google Scholar
• Kurata M, Okura T, Irita J, et al. The relationship between osteopontin and adiponectin in patients with essential hypertension. Clin Exp Hypertens 2010;32:358–63.
   PubMed Web of Science ®Google Scholar
• Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:14211–6.
   Google Scholar
• Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012;59:1069–1078.
   Google Scholar
• Wada T, Miyashita Y, Sasaki M, et al. Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. Am J Physiol Endocrinol Metab 2013;305:E1415–25.
   Google Scholar
• Sato A, Fukuda S. Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. J Hum Hypertens 2010;24:387–94.
   PubMed Web of Science ®Google Scholar
• Huang CC, Leu HB, Huang PH, et al. Hypertension Subtypes Modify Metabolic Response to Thiazide Diuretics. Eur J Clin Invest 2015 Nov 19. doi: 10.1111/eci.12571.
   Web of Science ®Google Scholar
• Francis J, Weiss RM, Wei SG, et al. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol 2001;281:H2241–51.
   PubMed Web of Science ®Google Scholar
• Toh R, Ishida T, Nishimura K, et al. Comparison of medium-dose losartan/hydrochlorothiazide and maximal-dose angiotensin II receptor blockers in the treatment of Japanese patients with uncontrolled hypertension: the Kobe-CONNECT Study. Hypertens Res 2012;35:1080–6.
   PubMed Web of Science ®Google Scholar
• Hamada T, Mizuta E, Kondo T, et al. Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients. Arzneimittelforschung 2010;60:71–5.
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Ohno E, Nakano N, et al. Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease. Clin Exp Hypertens 2011;33:366–72.
   PubMed Web of Science ®Google Scholar